Medicenna Therapeutics Corp. (MDNAF)
OTCMKTS
· Delayed Price · Currency is USD
0.938
-0.033 (-3.35%)
Jan 24, 2025, 4:00 PM EST
Medicenna Therapeutics Employees
Medicenna Therapeutics had 16 employees as of March 31, 2024. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,234,409
Market Cap
73.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 2,931 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 413 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
Silence Therapeutics | 109 |
SANUWAVE Health | 31 |
Medicenna Therapeutics News
- 6 weeks ago - Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 7 weeks ago - Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study - GlobeNewsWire
- 2 months ago - Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference - GlobeNewsWire
- 2 months ago - Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO) - GlobeNewsWire
- 2 months ago - Medicenna Therapeutics GAAP EPS of -C$0.05 - Seeking Alpha
- 2 months ago - Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update - GlobeNewsWire
- 2 months ago - Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire
- 2 months ago - Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - GlobeNewsWire